Medtronic (NYSE:MDT) Shares Unloaded Rep. Emily Randall

Representative Emily Randall (D-Washington) recently sold shares of Medtronic plc (NYSE:MDT). In a filing disclosed on February 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medtronic stock on January 6th. The trade occurred in the Representative’s “GARRET D. LEAHEY 2019 IRREVOCABLE F/B/O ALISON LEAHEY” account.

Representative Emily Randall also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 1/7/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Verizon Communications (NYSE:VZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Fortive (NYSE:FTV) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 1/6/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 1/6/2025.

Medtronic Price Performance

Shares of MDT opened at $92.27 on Friday. The stock has a 50 day simple moving average of $85.16 and a 200 day simple moving average of $86.68. Medtronic plc has a 52-week low of $75.96 and a 52-week high of $93.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.39 and a current ratio of 1.84. The firm has a market capitalization of $118.32 billion, a PE ratio of 28.22, a P/E/G ratio of 2.57 and a beta of 0.84.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.01. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. The company had revenue of $8.40 billion during the quarter, compared to analysts’ expectations of $8.27 billion. During the same quarter in the prior year, the company earned $1.25 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Sell-side analysts predict that Medtronic plc will post 5.45 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Friday, December 27th were issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend was Friday, December 27th. Medtronic’s dividend payout ratio (DPR) is presently 85.63%.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Robert W. Baird dropped their price target on Medtronic from $96.00 to $93.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Sanford C. Bernstein increased their price objective on Medtronic from $96.00 to $97.00 and gave the stock an “outperform” rating in a report on Wednesday, November 20th. Wells Fargo & Company cut their target price on Medtronic from $106.00 to $98.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. JPMorgan Chase & Co. decreased their price target on shares of Medtronic from $99.00 to $96.00 and set a “neutral” rating for the company in a research note on Friday, November 15th. Finally, Barclays lifted their price objective on shares of Medtronic from $105.00 to $109.00 and gave the company an “overweight” rating in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Medtronic has an average rating of “Hold” and an average target price of $95.00.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Brett A. Wall sold 12,437 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $90.00, for a total value of $1,119,330.00. Following the transaction, the executive vice president now directly owns 40,979 shares in the company, valued at $3,688,110. The trade was a 23.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Medtronic by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 124,203,387 shares of the medical technology company’s stock worth $9,921,367,000 after buying an additional 754,395 shares during the last quarter. State Street Corp lifted its position in shares of Medtronic by 0.9% in the third quarter. State Street Corp now owns 60,731,367 shares of the medical technology company’s stock valued at $5,509,155,000 after buying an additional 520,027 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Medtronic by 1.8% during the 4th quarter. Capital Research Global Investors now owns 33,203,685 shares of the medical technology company’s stock worth $2,652,310,000 after acquiring an additional 571,700 shares during the period. Geode Capital Management LLC increased its holdings in shares of Medtronic by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 27,056,217 shares of the medical technology company’s stock worth $2,155,085,000 after acquiring an additional 574,055 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Medtronic by 17.8% in the 4th quarter. Invesco Ltd. now owns 15,445,284 shares of the medical technology company’s stock valued at $1,233,769,000 after acquiring an additional 2,333,600 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

About Representative Randall

Emily Randall (Democratic Party) is a member of the U.S. House, representing Washington’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Randall (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 6th Congressional District. She declared candidacy for the 2026 election.

Emily Randall was born in Port Orchard, Washington, and lives in Bremerton, Washington. Randall earned bachelor’s degrees in Spanish and women’s studies from Wellesley College in 2008. Her career experience includes working as a development professional with Wellesley College, the San Francisco AIDS Foundation, Planned Parenthood Federation of America, and Legal Voice.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.